Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom
Rattachement africain : gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVES: We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) receiving recombinant von Willebrand factor (rVWF) in surgical settings in the United Kingdom. METHODS: Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first-time rVWF for the prevention/treatment of surgery-related bleeds, or the on-demand treatment of spontaneous/traumatic bleeds, between 1 October 2020 and 30 June 2022 at seven hospitals. Treatment, outcome and VWD-related HCRU data associated with the prevention/treatment of surgery-related bleeds were collected at first (index) event, for 12 months pre-index and 3-12 months post-index. RESULTS: Twenty patients (55.0% female, 90.0% White/Caucasian, mean age 56.7 years) received rVWF to prevent/treat surgery-related bleeds at index: normal haemostasis following abnormal bleeding was achieved for all applicable bleeds with limited requirement for additional treatments. Only four patients (all VWD type 2) received exogenous factor VIII in addition to rVWF at index. There were no treatment switches and no likely treatment-related complications. Physician-rated treatment satisfaction was 'excellent' (36.7%) or 'good' (63.3%) for all rVWF-treated surgery-related bleeds (n = 30). CONCLUSIONS: Results support the effectiveness and safety profile of rVWF in a surgical setting in adults with VWD, supplementing the growing body of evidence for rVWF.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom
- Date Crossref
- 11/10/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hammersmith Hospital Centre for Haematology pays non établi dans la noticeÉtablissement de santé
-
Imperial College London Centre for Haematology pays non établi dans la noticeUniversité ou école supérieure
-
Takeda (United Kingdom) pays non établi dans la noticeEntreprise
-
Knutsford and District Community Hospital pays non établi dans la noticeÉtablissement de santé
-
Takeda UK Ltd. London UK pays non établi dans la noticeEntreprise
-
HCD Economics Knutsford UK pays non établi dans la noticeInstitution
Centre for Haematology — Hammersmith Hospital, Centre for Haematology — Imperial College London et Takeda (United Kingdom), avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.